Dusan Stefoski to Treatment Outcome
This is a "connection" page, showing publications Dusan Stefoski has written about Treatment Outcome.
Connection Strength
0.155
-
Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders. J Neurol Sci. 2023 08 15; 451:120693.
Score: 0.031
-
The rare case of a 20-year-old male with rapidly progressive primary angiitis of the CNS with a good outcome. Neurol Neuroimmunol Neuroinflamm. 2020 09; 7(5).
Score: 0.025
-
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26; 16:117.
Score: 0.019
-
Is cervical decompression beneficial in patients with coexistent cervical stenosis and multiple sclerosis? J Clin Neurosci. 2014 Dec; 21(12):2189-93.
Score: 0.017
-
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014 May; 13(5):472-81.
Score: 0.016
-
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler. 2014 Apr; 20(4):464-70.
Score: 0.016
-
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22; 381(9884):2167-75.
Score: 0.015
-
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009 Mar; 8(3):244-53.
Score: 0.011
-
Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 1998 Nov 15; 92(10):3505-14.
Score: 0.006